WeLeader Biomedical Co., Ltd. (TPEX:7713)
Taiwan · Delayed Price · Currency is TWD 73.50
+0.60 (0.82%)
Aug 26, 2026, 1:13 PM CST
WeLeader Biomedical Revenue
WeLeader Biomedical had revenue of 339.12M TWD in the quarter ending June 30, 2026, with 24.18% growth. This brings the company's revenue in the last twelve months to 1.21B, up 18.35% year-over-year. In the year 2025, WeLeader Biomedical had annual revenue of 1.11B with 11.92% growth.
Revenue (ttm)
1.21B
Revenue Growth
+18.35%
P/S Ratio
2.76
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 118.18M | 11.92% |
| Dec 31, 2024 | 991.13M | 50.43M | 5.36% |
| Dec 31, 2023 | 940.70M | -95.02M | -9.17% |
| Dec 31, 2022 | 1.04B | 194.58M | 23.13% |
| Dec 31, 2021 | 841.14M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hi-Clearance | 4.41B |
| Wellell | 2.50B |
| OK Biotech | 1.54B |
| Dynamic Medical Technologies | 1.40B |
| AViTA | 972.61M |
| A Plus Biotechnology | 887.93M |
| Medimaging Integrated Solution | 682.01M |
| Delta Asia International | 678.17M |